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OBJECTIVES This registry collected the 30-day and 9-month clinical outcomes of patients whose coronary stent
implantation was suboptimal, and compared them with the cohort of patients with “optimal”
stenting in the randomized portion of the STent Anti-thrombotic Regimen Study (STARS) trial.
BACKGROUND Although “optimal” stenting combined with an aspirin and ticlopidine regimen carries a low
(0.5%) incidence of subacute stent thrombosis, only limited data are available for patients in
whom stents are deployed suboptimally.
METHODS In the STARS, 312 (15.9%) of 1,965 patients enrolled were excluded from participation in
the randomized trial based on a perceived “suboptimal” result of coronary stenting. Of these,
265 patients met prespecified criteria for suboptimal stenting, and were followed in a parallel
registry, which was compared with the randomized STARS optimal stenting cohort. The
primary end point was a 30-day composite of death, emergent target lesion revascularization,
angiographic thrombosis of the target vessel without revascularization and nonfatal myocar-
dial infarction (MI)unrelated to direct procedural complications.
RESULTS Registry patients had a similar frequency of the primary end point compared with the overall
randomized cohort (3.0% vs. 2.2%), with this end point correlating to use of multiple stents,
smaller final lumen diameter and absence of ticlopidine from the poststent regimen. Overall
30-day mortality (1.1% vs. 0.06%, p 5 0.009) and periprocedural non-Q wave MI (8.7% vs.
4.2%, p 5 0.003) were more frequent in registry patients, and appeared to be related to acute
procedural complications. Clinical restenosis was significantly higher for registry patients
(26.8% vs. 16.0%, p 5 0.001), relating to greater prevalence of independent predictors such
as smaller final lumen diameter and multiple stent use.
CONCLUSIONS In the STARS registry, the inability to perform optimal stenting correlated with smaller final
lumen diameter and longer stent length. With ticlopidine-containing regimens, the acute
clinical results of “suboptimal” stent deployment are clinically acceptable, although they are
not quite as good as those of optimal stenting using similar drug therapy. (J Am Coll Cardiol
1999;34:698–706) © 1999 by the American College of Cardiology
Just five years after their approval for intracoronary use in
the U.S., stents are now used in 50% to 70% of all
percutaneous coronary interventions. This rapid growth has
been driven by trials demonstrating that implantation of the
Palmaz-Schatz coronary stent offers significant benefits over
balloon angioplasty in terms of both acute procedural
success and long-term patency (1,2). To prevent subacute
stent thrombosis, however, these pivotal trials relied on
aggressive poststent antithrombotic regimens, which in-
cluded aspirin, dipyridamole, intravenous low-molecular
weight Dextran and an uninterrupted crossover from intra-
venous heparin to oral coumarin. Although these regimens
decreased the incidence of subacute stent thrombosis (to
approximately 3.5%, compared with the nearly 20% inci-
dence reported in earlier stent studies) (3), this was achieved
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only at the expense of a significant increase in bleeding,
vascular complications and length of hospital stay (1,2,4).
More recently, registry data have shown that the use of
“optimal” stent technique (including routine high-pressure
balloon dilation after initial stent deployment) allows use of
only antiplatelet agents (aspirin and ticlopidine) to yield
similar or even lower stent thrombosis rates without exces-
sive hemorrhagic complications (5–7). The superiority of
aspirin and ticlopidine over aspirin and coumarin has been
demonstrated in one single-center randomized trial of stent
placement in high-risk patients (8), and in the randomized
STent Anti-thrombotic Regimen Study (STARS). This
large multicenter randomized trial demonstrated that stent
thrombosis was significantly lower in patients assigned to
aspirin plus ticlopidine (0.5%) compared with aspirin plus
coumarin (2.7%) or the aspirin alone (3.6%) regimen (9).
Randomization in STARS, however, was predicated on
having achieved “optimal” stent results (9). Patients who
failed to achieve these results were not so randomized, but
rather, entered into a parallel nonrandomized registry where
the antithrombotic regimen was selected by the operator.
Clinical follow-up, however, was identical to that in the
randomized cohort. The purpose of this analysis is to
compare the 30-day clinical outcomes and late clinical
restenosis outcomes for patients in the suboptimal stenting
STARS registry with “optimal” stenting patients in the
main randomized STARS trial.
METHODS
Study design and patient selection. The details of the
STARS design and analysis plan have been previously
reported (9). In summary, all patients undergoing elective
coronary stent procedures at the 50 participating investiga-
tional sites in the U.S. were screened for enrollment.
Patients were deemed eligible if they had one or two target
lesions with .60% diameter stenosis in a 3- to 4-mm
reference diameter native coronary artery, which did not
involve the left main coronary or a major bifurcation. Other
exclusion criteria were additional stenoses within the target
vessels, myocardial infarction (MI) within seven days,
known contraindications to study drugs (aspirin, ticlopidine
or coumarin) and a history of bleeding diathesis. “Optimal”
results were defined as: 1) achieving ,10% residual diam-
eter stenosis within the stented segment (by visual estimate);
2) no evidence of poststent thrombus; 3) no evidence of
severe dissection (NHLBI grade $D) or abrupt closure
anytime during the procedure or significant poststent dis-
section (NHLBI grade .B); 4) thrombolysis in myocardial
infarction (TIMI) 3 flow; and 5) no more than two
Palmaz-Schatz stents used to treat one long (#25-mm-
length) lesion or two focal (#12-mm-length) lesions in one
or two native coronary arteries. To facilitate optimal results,
stent implantation was routinely followed by high-pressure
dilation. Patients with “optimal” results were eligible to be
randomly assigned to one of the three antithrombotic drug
regimens. Patients who did not meet all of the optimal
angiographic criteria were entered into a parallel registry, in
which anti-thrombotic regimens were left to the discretion
of the investigator. The results of this registry are reported
in this communication.
Of 1,965 patients enrolled in STARS, 1,653 patients met
angiographic criteria for “optimal” stent placement and were
randomized; the remaining 312 (15.9%) patients were
entered in the registry. Of these 312 registry patients, 47
patients were eliminated from further analysis: 27 met all
angiographic criteria for randomization but were assigned to
the registry at the investigator’s discretion. In addition, 8
patients never received a stent due to delivery failure, 11
patients were transferred directly from the cardiac catheter-
ization laboratory for emergency bypass surgery, and 1
patient died during the stenting procedure. The remaining
265 patients with suboptimal stenting procedures thus
comprise the primary population for this analysis.
Data collection and end point analysis. Detailed case
report forms were completed by the clinical coordinator at
each site, monitored by independent study monitors and
submitted to the data coordinating center (Cardiovascular
Data Analysis Center [CDAC], Department of Medicine,
Harvard Medical School and Beth Israel Deaconess Med-
ical Center, Boston, Massachusetts). All electrocardiograms
were interpreted by the Electrocardiographic Core Labora-
tory blinded to clinical events and cardiac enzyme data
(ECG Core Laboratory, CDAC, Boston, Massachusetts).
Procedural angiograms were submitted to the Angiographic
Core Laboratory (Washington Hospital Center, Washing-
ton, DC), where they were analyzed using the CMS system
(Medis, Leiden, The Netherlands). Clinical follow up for
adverse events (death, recurrent ischemia and MI, repeat
revascularization, bleeding and vascular complications) was
obtained at hospital discharge, 30 days, 6 months and 9
months.
Study end points. The primary end point of the study was
a patient-based 30-day hierarchical composite of: 1) death,
2) emergent target lesion revascularization, 3) angiographic
thrombosis of the target vessel without revascularization or
4) nonfatal MI unrelated to direct procedural complications.
Secondary end points included acute procedure success,
procedure-related MI, hematologic dyscrasia, major bleed-
ing, vascular complications, target lesion revascularization
Abbreviations and Acronyms
MI 5 myocardial infarction
QMI 5 Q wave myocardial infarction
STARS 5 STent Anti-thrombotic Regimen Study
TIMI 5 thrombolysis in myocardial infarction
TLR 5 target lesion revascularization
TVF 5 target vessel failure
TVR 5 target vessel revascularization
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(TLR), target vessel revascularization (TVR) and target
vessel failure (TVF), defined as death, MI or TVR. All
deaths within 30 days were considered procedure related.
Acute procedure success was defined as achievement of
,50% residual diameter stenosis and freedom from death,
or emergent bypass surgery. Myocardial infarction was
defined as new pathologic Q waves in two or more contig-
uous leads as determined by the ECG Core Laboratory or a
creatine kinase more than twice the upper limit of normal in
the presence of elevated creatine kinase-MB isoform (CK-
MB). To ensure complete ascertainment of procedural CK
elevations, serial CK and MB fractionation were obtained
immediately and every 6 to 8 h after the procedure, for at
least 24 h or the time of hospital discharge. Myocardial
infarctions that were attributed entirely to acute procedure
related complications were not considered as part of the
composite end point. Major bleeding complications were
defined as any bleeding episode requiring transfusion. Vas-
cular complications were defined as any vascular access
complication requiring surgical repair or ultrasound com-
pression. All clinical events were adjudicated by an inde-
pendent Clinical Events Committee.
Statistical analysis. The analysis of the STARS registry
was designed to compare 30-day and 9-month clinical
outcomes of patients after suboptimal stent implantation to
the pooled randomized patients with optimal stent results.
All statistical analyses were performed using the SAS for
Windows versions 6.08-6.12 (SAS Institute, Cary, North
Carolina). Continuous variables are expressed as mean 6
standard deviation and were compared using t tests or
Wilcoxon nonparametric tests. Discrete variables are ex-
pressed as counts and percentages and were compared using
chi-square or Fisher exact tests. Stepwise multivariable
logistic regression models of the 30-day primary end point
and nine-month target vessel failure in the entire STARS
cohort were used to simultaneously evaluate effect of base-
line predictors, antithrombotic treatment, procedural results
and registry enrollment (10). Survival estimates were com-
puted using Kaplan-Meier methods and compared using
log-rank tests.
RESULTS
Patient characteristics and indication for registry enroll-
ment. Patients enrolled in the registry were more likely to
have multivessel coronary artery disease than randomized
patients (42% vs. 32%, p , 0.01), but had otherwise similar
baseline clinical features to STARS-randomized patients
(Table 1).
All indications for enrollment in the registry rather than
the randomized trial are listed according to actual incidence
and hierarchical order in Table 2. The most common reason
for enrollment in the registry was requirement for .2
Palmaz-Schatz stents, with 136 (51%) registry patients
receiving such multiple stents to treat a longer lesion length
or a procedural complication.
Lesion characteristics and baseline quantitative angiog-
raphy. Patients enrolled in the registry had more complex
coronary lesion morphology before stenting (Table 3).
Registry patients also had slightly longer lesions before
treatment, and final percent diameter stenosis was slightly
higher (Table 4).
Procedural results. Because multiple stent (.2 Palmaz-
Schatz 15-mm stents) use was the most common indication
for nonrandomization and registry enrollment, only 28% of
lesions in registry patients were covered by a single 15-mm
Palmaz-Schatz stent, with 21% requiring a second stent and
51% requiring 3 or more stents. In contrast, most lesions in
randomized patients (72%) were covered by a single stent,
with only 28% requiring a second stent. Overall, registry
patients received 2.3 6 1.2 stents per vessel compared with
1.3 6 0.4 for randomized patients. Final balloon/artery ratio
(1.1 6 0.2 vs. 1.1 6 0.2) and the mean final postdilation
pressure (17.1 6 3.2 vs. 17.5 6 3.0 atmospheres), however,
were nearly identical for registry and randomized lesions.
Acute lesion success (,50% diameter stenosis after final
Table 1. Baseline Clinical Characteristics
Registry
Pooled
Randomized
Number of patients 266 1,653
Age (yr; mean 6 SD) 62 6 11 61 6 11
Female (%) 30 29
Diabetes (%) 17 19
Cigarette smoking (%) 24 28
Dyslipidemia (%) 36 34
Family history (%) 32 31
Prior CABG (%) 8 8
Restenotic lesion (%) 17 16
Prior MI (%) 35 36
Multivessel disease (%) 42 32*
Unstable angina (%) 60 60
LVEF (%) 56 6 12 56 6 11
*p 5 0.01 for registry vs. randomized.
CABG 5 coronary artery bypass graft; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction.
Table 2. Indications for Registry Enrollment (n 5 265)
Indication
Absolute
n (%)
Hierarchical
n (%)
Final flow , TIMI 3 10 (3.8) 10 (3.8)
Final dissection $ NHLBI
grade B
89 (33.5) 82 (30.9)
Thrombus 18 (6.8) 12 (4.5)
Dissection $ NHLBI grade D
or abrupt closure anytime
51 (19.2) 30 (11.3)
Residual stenosis .10% 52 (19.6) 37 (14.0)
Three or more stents in target
vessel
136 (51.3) 94 (35.5)
NHLBI 5 National Heart, Lung, and Blood Institute; TIMI 3 5 Thrombolysis in
Myocardial Infarction.
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treatment) was extremely high in both groups (97.7% for
registry and 99.4% for randomized lesions). Final diameter
stenosis was slightly but significantly higher for registry
lesions (10.3 6 12.8% vs. 8.5 6 11.4%, p 5 0.013; Fig. 1).
Antithrombotic treatment regimens. Table 5 shows the
antithrombotic regimens selected by the investigator for
registry patients. Aspirin and ticlopidine were part of this
regimen in 79% of patients, and were used as the sole
therapy in 44%. Thirty-four percent of patients received a
combination containing coumarin, and 10% of patients
received subcutaneous low molecular weight heparin. Ad-
junctive abciximab was used in only 9% of registry patients.
Clinical end points. ACUTE 30-DAY EVENTS. The com-
bined 30-day end point (death, Q wave MI [QMI], emer-
gent target lesion revascularization or angiographic docu-
mentation of stent occlusion) occurred in 3% of registry
patients compared with 2.2% of randomized patients (p .
0.20, Table 6). This included 3 registry patients who died
within 30 days: 1 patient had sudden death two weeks after
an index procedure was complicated by severe dissection,
multiple stents, urgent coronary artery bypass graft and
QMI; 1 patient had subacute stent thrombosis, anterior MI
and refractory ventricular fibrillation 2 weeks after an index
procedure, which was complicated by persistent dissection
and need for multiple stents; 1 patient had massive brain
stem hemorrhage 2 weeks after the index procedure while
on aspirin, ticlopidine and coumarin for residual thrombus
after stenting. Non-QMI (total CK more than two times
normal with elevated CK-MB) was twice as common in
registry patients (8.7% vs. 4.2%, p 5 0.003). There was also
a trend for increased vascular or hemorrhagic complications
requiring transfusion or surgical repair in registry patients
(5.3% vs. 3.0%, p 5 0.10).
Thirty-day events in the registry varied significantly with
the antithrombotic regimen selected by the operator, being
least for aspirin plus ticlopidine (Table 5). The only death
that was related to stent thrombosis occurred in a patient
who did not receive postprocedure ticlopidine. For the
30-day combined end point, the results of aspirin plus
ticlopidine (6 coumarin) were comparable with the ticlo-
pidine arm of the randomized trial (0.6% vs. 0.5%). A
comparison of all patients receiving ticlopidine versus those
not receiving ticlopidine showed a strong statistical trend in
favor of ticlopidine treatment (1.9% vs. 7.4%, p 5 0.057).
NINE-MONTH CLINICAL FOLLOW UP. At 9 months (Table
6), clinical follow up was complete in 99% of patients,
showing major adverse cardiac events (death, MI, TLR)
that were significantly higher for registry patients. This
difference was driven by the increase in procedure-related
non-QMI as well as increased TLR (15.4% vs. 10.3%, p 5
0.013).
Table 3. Baseline Angiographic Characteristics
Registry
Pooled
Randomized
Vessel location
Left anterior descending (%) 34 43†
Circumflex (%) 21 20
Right coronary (%) 45 37
Baseline characteristics
Eccentric (%) 39 42
Calcification (%) 26 20*
Bend .45° (%) 16 9‡
Tortuosity (%) 8 6
Thrombus (%) 4 4
Total occlusions (%) 3 2
Lesion morphology (ACC/AHA)
A 9 9
B1 20 28
B2 56 55
C 15 8‡
*p , 0.05; †p , 0.01; ‡p , 0.001 for registry vs. randomized.
ACC/AHA 5 American College of Cardiology/American Heart Association.
Table 4. Quantitative Angiographic Results
Registry
Pooled
Randomized
Baseline
Reference diameter (mm) 2.99 6 0.49 3.02 6 0.50
Lesion MLD (mm) 1.02 6 0.48 1.01 6 0.45
Diameter stenosis (%) 66 6 14 66 6 13
Lesion length (mm) 12.3 6 7.3 10.7 6 5.5†
Postprocedure
In-stent MLD (mm) 2.78 6 0.47 2.80 6 0.43
Acute gain 1.73 6 0.60 1.77 6 0.50
In-stent diameter stenosis (%) 10 6 13 8 6 11*
*p 5 0.01, †p , 0.001 for registry vs. randomized.
MLD 5 minimum lumen diameter.
Figure 1. Cumulative distribution frequency of percent diameter
stenosis at baseline (pre) and after final stent postdilation (post). At
baseline, there is no difference in stenosis severity for registry
compared with randomized patients. The final diameter stenosis is
slightly, but significantly, worse for registry patients.
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Survival free from TVF (death, MI or TVR) was thus
significantly lower in registry compared with randomized
patients (72.9 vs. 83.6%, p 5 0.0001) (Fig. 2).
Predictors of the 30-day composite end point and nine-
month target vessel failure. In stepwise multivariable mod-
els of the 30-day combined adverse event end point, indepen-
dent predictors included final minimal lumen diameter (OR
0.14/mm, p 5 0.0001), larger number of stents (OR 5
2.1/stent, p 5 0.0002) and absence of poststent ticlopidine
therapy (OR 5.3, p 5 0.0004). After adjustment for these
variables, neither final dissection nor enrollment in the registry
per se was an independent predictor of the 30-day primary end
point.
Stepwise multivariable models of TVF at nine months
Table 5. Antithrombotic Medications in Registry Patients and Relationship to Primary End
Point and Transfusion
N 5 265
n (%)
Primary End Point
n (% per drug)
Transfusion
n (% per drug)
Antithrombotic regimen
Aspirin only 13 (4.9) 1 (7.7) 2 (15.4)
Aspirin 1 ticlopidine 118 (44.5) 0 (0) 5 (4.2)
Aspirin 1 warfarin 34 (12.8) 3 (8.8) 0 (0)
Aspirin 1 warfarin 1 ticlopidine 46 (17.4) 1 (2.2) 2 (4.3)
Other combinations 54 (20.4) 3 (5.5) 3 (5.6)
Individual drug usage
Ticlopidine 211 (79.3) 4 (1.9) 9 (4.3)
Warfarin 90 (33.8) 5 (5.5) 3 (3.3)
Low-molecular weight heparin 28 (10.5) 1 (3.6) 1 (3.6)
Abciximab 23 (8.6) 3 (13.0) 2 (8.7)
Dipyridamole 6 (2.3) 0 (0) 0 (0)
Table 6. Clinical Follow up
Registry
(n 5 265)
Pooled Randomized
(n 5 1,653) p-Value
30-day events
Primary composite end point* 3.0 2.2 . 0.20
Death (%) 1.1 0.06 0.009
MI† (%) 11.3 5.4 , 0.001
QMI (%) 2.6 1.2 0.09
Non-QMI (%) 8.7 4.2 0.003
Repeat TVR (%) 3.8 2.3 0.20
CABG (%) 1.5 0.3 0.03
Repeat PTCA only (%) 2.3 2.0 . 0.20
Stent reocclusion (angiographic) 2.3 2.0 . 0.20
Vascular or bleeding complication (%) 5.3 3.1 0.10
Surgical repair 0.8 1.0 . 0.20
Transfusion (%) 4.5 2.6 0.11
9-month cumulative events
Death (%) 1.9 0.9 0.17
MI (%) 11.7 5.8 , 0.001
QMI (%) 2.6 1.2 0.09
Non-QMI (%) 9.1 4.6 0.004
Target lesion revascularization (%) 15.5 10.2 0.015
Repeat PTCA only (%) 8.7 7.4 . 0.20
CABG (%) 6.8 2.8 0.002
Target vessel revascularization (%) 17.4 12.1 0.02
Target vessel failure (%) 26.8 16.0 , 0.001
*Death, emergent target lesion revascularization, angiographic thrombosis of the target vessel without revascularization or
nonfatal MI unrelated to direct procedure complications. †Includes procedure-related MI.
CABG 5 coronary artery bypass graft; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty; QMI 5 Q wave myocardial infarction.
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showed that predictors included final minimal lumen diam-
eter (OR 0.36/mm, p 5 0.0001), larger number of stents
(OR ratio 1.40/stent, p 5 0.0007) and a history of diabetes
(OR 1.42, p 5 0.049). After adjustment for these variables,
enrollment in the registry was no longer an independent
predictor of nine-month TVF.
Excluded registry patients. Of the 312 patients originally
assigned to the registry, 47 were excluded from this analysis
because they did not meet the criteria for suboptimal stent
results. Twenty-seven patients actually met all angiographic
criteria for randomization but were assigned to the registry
by the operator. Most of these cases involved failure to meet
other inclusion criteria, which was not recognized before
enrollment. None of these patients experienced the 30-day
combined end point, died or had an MI during the
follow-up period. There were six patients (22.2%) who
required TVR. Eleven other patients who sustained serious
angiographic complications during the stenting procedure
and who were sent directly from the cardiac catheterization
laboratory to emergency bypass surgery were also excluded.
One of these patients suffered a QMI, and four patients had
a non-QMI. There were no deaths or late target vessel
events among these patients. In addition, eight patients who
never received a study stent due to delivery failure were
excluded. Two of these patients were referred for urgent
bypass surgery, and six were treated with successful balloon
angioplasty. There were no acute deaths or MI in this group
and no patient required repeat revascularization. One pa-
tient was readmitted three months later for non-QMI.
Finally, one patient who died during the stent procedure
from spontaneous pulmonary hemorrhage was also excluded
from this analysis.
DISCUSSION
Although the primary component of STARS was a ran-
domized trial comparing three antithrombotic regimens
after “optimal” stenting, 312 (15.9%) of 1,965 patients who
consented to participate in the randomized trial were
enrolled instead into a parallel registry of suboptimal stent-
ing. For 265 of these patients, this decision was based on
failure to obtain “optimal” stent results, defined as no more
than two 15-mm Palmaz-Schatz stents, a ,10% final
residual stenosis, no final dissection . NHLBI grade B, no
interim thrombus, abrupt closure or dissection . NHLBI
grade D at any time during the procedure and normal
(TIMI grade 3) flow. Patients in the registry were more
likely to have multivessel coronary artery disease (42% vs.
32%, p 5 0.01) and complex lesion morphology (ACC/
AHA class C, 15% vs. 8%, p , 0.01), which explains their
increased frequency of dissections and the need for multiple
stents. Indeed, the requirement for multiple stents was the
most common reason for failure to meet randomization
criteria that led to enrollment in the registry. By using
similar poststent dilation pressures and balloon/artery ratios
as for the randomized cohort, however, investigators were
able to achieve final lesion success (,50% diameter stenosis
with TIMI 3 flow) in the registry that nearly matched the
excellent results seen in the randomized patients (97.7% vs.
99.4%, p . 0.20).
Acute clinical outcomes. The combined 30-day end point
of death, emergent TLR, angiographic reocclusion without
revascularization and acute MI (other than simple low-level
periprocedural CK elevation) was selected as a surrogate for
stent thrombosis. This combined end point was not differ-
ent for registry compared with randomized patients overall
(3.0% vs. 2.2%, p . 0.20). Registry patients who received
ticlopidine therapy had an even lower rate of the combined
end point (ASA and ticlopidine only, 0%; any ticlopidine-
containing combination, 1.9%), similar to results seen with
ticlopidine in the randomized optimal stenting patients (9).
Patients who received ASA plus continued anticoagulation
with heparin and coumarin in the absence of ticlopidine had
Figure 2. Estimated freedom from TVF for registry compared with randomized patients. There is a significant increase in TVF events
early for registry patients with further separation of the survival curves during the first year, consistent with increased frequency of
periprocedural MI as well as later target vessel revascularization.
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significantly higher rates of the 30-day end point (8.8%)
than seen in the corresponding arm of the randomized trial
(2.9%). Patients who received the combination of aspirin,
coumarin and ticlopidine, however, had an event rate of
2.2%. This suggests that the high thrombosis rate on ASA
and coumarin reflects lack of ticlopidine protection, rather
than a toxic effect of coumarin.
Using a more conservative definition for stent thrombosis
(one requiring angiographic documentation of stent reoc-
clusion) registry patients again compared favorably with the
randomized cohort (2.3% vs. 2.0%). Smaller final lumen
dimension, multiple stent use and absence of ticlopidine
independently predicted stent thrombosis.
Registry patients did, however, have a significantly higher
incidence of 30-day mortality (1.1% vs. 0.06%, p , 0.009)
and periprocedural non-QMI (8.7% vs. 4.2%, p 5 0.003)
than seen in the randomized cohort. Two of the three early
deaths in the registry were clearly due to complications of
the procedure, including one that resulted in subacute stent
thrombosis, and the third may have been related to a more
aggressive anticoagulation regimen that was selected be-
cause of the suboptimal results. Although only one of these
deaths occurred in patients receiving ticlopidine, it is unclear
if the choice of antithrombotic treatment had any effect on
the outcome. We have previously reported that the inde-
pendent predictors of MI after stenting in the STARS study
were lesion length, major angiographic complications and
failure to achieve a large final minimal lumen diameter.
Both lesion length and angiographic complications were
more common in registry patients, so a higher incidence of
non-QMI is not surprising. It is important to note, how-
ever, that these periprocedural non-QMIs after an otherwise
successful STARS procedure were not associated with an
increase in any adverse outcome, including late mortality or
recurrent MI, during one-year follow up (11).
There was a trend for registry patients to have more
vascular complications requiring surgery or transfusion than
randomized patients (5.3% vs. 3.0%, p 5 0.10). This may
have been due to the more common continuation of
intravenous heparin in registry compared with randomized
patients. Similar to results in randomized patients, anti-
platelet therapy with ASA and ticlopidine was not associ-
ated with a significant reduction in rates of bleeding
requiring transfusion compared with anticoagulant-
containing regimens. This suggests that much of the ob-
served reduction in hemorrhagic complications since early
stent trials relates to better timing and technique for sheath
removal, rather than a significantly lower bleeding propen-
sity on newer antiplatelet drug regimens.
Clinical restenosis. Clinically evident restenosis at nine
months, defined as repeat TLR (15.5% vs. 10.2%, p 5
0.015), or, more broadly, as TVF (26.8% vs. 16.0%, p ,
0.001), was significantly higher for registry than randomized
patients. This appears to have been based on the greater
prevalence of smaller lumens and multiple stent use in the
registry, rather than a prorestenotic effect of being in the
registry itself. Because routine angiographic follow up was
not performed, it is not possible to relate this increase in
clinical restenosis to angiographic binary restenosis (.50%
diameter stenosis) and other parameters of angiographic
restenosis (e.g., loss index). Lack of angiographic follow up
in both the STARS registry and randomized trial, however,
allows for accurate assessment of clinical restenosis without
the bias introduced by routine angiographic follow up to
significantly increase the observed rates of TLR (12,13).
Comparison with previous studies. Acute clinical out-
comes for patients enrolled in the STARS registry after
suboptimal stenting compare favorably with other reports in
the modern era of routine high-pressure postdilation and
antiplatelet therapy. Moussa et al. (7) noted a 1.9% subacute
stent thrombosis rate in 1,042 patients treated with only
antiplatelet therapy after intravascular ultrasound-guided
stent placement. Multiple stent use, residual dissections and
slow flow were the independent predictors of subacute
thrombosis in this group. This thrombosis rate is identical
to that observed in ticlopidine-treated patients in the
STARS registry. In the STARS registry, however, final
dissection and slow flow were not predictors of stent
thrombosis, perhaps as the result of a strategy that allowed
for use of multiple stents so that comparatively few lesions
were left with significant residual dissection ($ NHLBI
grade C) or reduced flow.
Schomig et al. (8) reported on 517 patients randomized
to aspirin and ticlopidine or aspirin and coumarin after
successful stenting for nonelective indications. The 1.6%
primary cardiac end point in the ticlopidine group was
almost identical to the ticlopidine-treated patients in the
STARS registry (1.9%). These authors, however, attributed
significantly higher (6.2%) rate of thrombosis in the anti-
coagulant (coumarin) group to a toxic platelet activation
effect in patients who received continued anticoagulant
therapy with heparin and coumarin. In contrast, the
STARS randomized trial showed that coumarin therapy
was not associated with an increased risk of stent thrombosis
compared with aspirin alone. The incidence of stent throm-
bosis in the registry patients receiving coumarin (any cou-
marin 5.5%, aspirin plus coumarin combination 8.8%) is
substantially higher than in the corresponding STARS
randomized arm (aspirin plus coumarin 5 2.9%). Although
Schomig et al. (8) believed that this was due to a toxic effect
of anticoagulant therapy (predisposition to stent thrombo-
sis, perhaps through platelet activation) (14), both the
STARS randomized trial and the suboptimal registry sug-
gest that a more plausible explanation for the high throm-
bosis rates with ASA plus coumarin is the lack of protective
effect of ticlopidine. This is apparent in the 2.2% incidence
of stent thrombosis in patients receiving aspirin, coumarin
and ticlopidine, which was significantly less than other
coumarin combinations (5% to 8%) and not significantly
different from the results with aspirin plus ticlopidine.
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Despite excellent results in terms of the 30-day combined
end point, late clinical restenosis in the STARS registry was
significantly more common than in the randomized patients
(TVF, 26.8% vs. 16.0%, p , 0.001). This finding is
consistent with a study by Mathew et al. (15), which
followed 45 patients treated with three or more stents for
indications of threatened or abrupt closure. Lesion success
was over 97%, but by six months, 23.3% of patients
experienced death, MI or repeat target vessel revasculariza-
tion. Kastrati et al. (16) examined predictors of clinical and
angiographic restenosis in over 1,000 consecutive stent
patients. The strongest predictors of clinical restenosis were
the same as those identified in our study, namely, smaller
final lumen diameter, use of multiple stents and diabetes
mellitus.
Conclusions. About 15% of patients undergoing stenting
of favorable lesions have suboptimal stenting, most com-
monly because of residual dissections or the need for
multiple (three or more) stents. With the use of aggressive
high-pressure postdilation, such patients still can have
excellent acute results that do not differ significantly from
those in the randomized cohort of “optimal” stenting in
terms of lesion success (97.8% vs. 99.4%), 30-day adverse
clinical events (3.0% vs. 2.1%) and documented stent
thrombosis (2.3% vs. 2.0%). Similar to the findings in the
randomized STARS cohort, the rates of stent thrombosis
were significantly less for patients treated with a ticlopidine-
containing regimen. Thus, there is no information in the
STARS trial or elsewhere suggesting that more aggressive
antithrombotic regimens beyond aspirin and ticlopidine
further reduce subacute thrombosis, even in suboptimally
treated patients. The observed higher 30-day mortality rate
and increased frequency of non-QMI appears to be directly
related to acute procedural complications. Further studies
will be required to determine if pretreatment with ticlopi-
dine, use of alternative antiplatelet agents such as clopi-
dogrel or addition of IIb/IIIa inhibitors will modify these
acute outcomes or further reduce subacute stent thrombosis
events after similar suboptimal results. Late clinical resten-
osis (TLR, 15.5% vs. 10.2%, p 5 0.015; TVF, 26.8% vs.
16.0%, p , 0.001) was also significantly more common in
registry patients, reflecting their smaller final minimum
lumen diameter and multiple stent use. With these caveats,
the clinical results of “suboptimal” stent deployment with
ticlopidine-containing regimens are clinically acceptable and
compare well with those of optimal stenting with similar
drug therapy.
Limitations. This registry analysis has several limitations.
The first limitation is the small population size and the
exclusive use of the Palmaz-Schatz stent. A study of a larger
number of patients with suboptimal stent results or similar
patients treated with other available stents may have found
significant differences for the combined 30-day end point
compared with patients with optimal results. Nevertheless,
this study represents the largest reported series of patients
with suboptimal stent results in the modern era of routine
high-pressure poststent dilation and antiplatelet therapy,
and there is little evidence from current stent-versus-stent
trials that suggest major difference in the thrombotic behav-
ior of other devices. The second limitation is that conclu-
sions regarding antithrombotic regimens are limited, be-
cause these regimens were assigned by operator preference
rather than in a randomized fashion. Although we could not
demonstrate it by objective criteria, had operators chosen
one regimen (e.g., coumarin) for worse stent results, the
negative outcomes of that therapy may have been partially
the result of this selection bias rather than a shortcoming of
the drug regimen itself. Our findings of the protective effect
of ticlopidine, however, are supported by the results of two
large randomized trials of optimal stent results. The third
limitation is that the absence of angiographic follow up
prevents the determination of restenosis parameters, such as
late loss and loss index. Clinical restenosis, however, has
been shown to correlate closely with angiographic resteno-
sis, and by not subjecting patients to routine angiographic
followup, a potential bias toward increased repeat target
lesion revascularization may be avoided. The fourth limita-
tion is that the registry did not adequately assess the role of
IIb/IIIa inhibitor therapy, due to infrequent use of this
class of drugs (9% of registry patients). Reports from the
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
(EPISTENT) trial (17) suggest that routine use of such
agents may have decreased the incidence of CK elevations
after suboptimal stenting, although the long-term benefits
of such treatment are still uncertain. Finally, the results from
the STARS registry may not be generalizable to settings of
more complex lesion morphology, or abrupt closure/
threatened closure in which more severe dissection may be
combined with reduced flow that is not improved with use
of additional stents. In these situations, there may be benefit
to supplementing aspirin and ticlopidine with additional
antithrombotic therapy, including IIb/IIIa inhibitors.
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